See more : Krishna Capital & Securities Limited (KRISHNACAP.BO) Income Statement Analysis – Financial Results
Complete financial analysis of CTI BioPharma Corp. (CTIC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CTI BioPharma Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Datalogic S.p.A. (DAL.MI) Income Statement Analysis – Financial Results
- Solaris Energy Infrastructure Inc. (SEI) Income Statement Analysis – Financial Results
- Shahlon Silk Industries Limite (SHAHLON.BO) Income Statement Analysis – Financial Results
- Mitsu Chem Plast Limited (MITSU.BO) Income Statement Analysis – Financial Results
- Cyclopharm Limited (CYC.AX) Income Statement Analysis – Financial Results
CTI BioPharma Corp. (CTIC)
About CTI BioPharma Corp.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 53.95M | 0.00 | 0.00 | 3.35M | 26.29M | 25.15M | 57.41M | 16.12M | 60.08M | 34.68M | 0.00 | 0.00 | 319.00K | 80.00K | 11.43M | 127.00K | 80.00K | 16.09M | 29.59M | 24.77M | 16.90M | 6.24M | 502.04K | 100.00K | 13.20M | 11.80M | 9.10M |
Cost of Revenue | 3.51M | 161.00K | 4.20M | 0.00 | 879.00K | 364.00K | 1.38M | 1.94M | 895.00K | 137.00K | 0.00 | 0.00 | 0.00 | 0.00 | 3.24M | 49.00K | 0.00 | 518.00K | 1.10M | 840.00K | 423.00K | 394.00K | -1.02M | -2.20M | -1.90M | -1.60M | 14.30M |
Gross Profit | 50.43M | -161.00K | -4.20M | 3.35M | 25.41M | 24.78M | 56.03M | 14.18M | 59.18M | 34.54M | 0.00 | 0.00 | 319.00K | 80.00K | 8.19M | 78.00K | 80.00K | 15.57M | 28.49M | 23.93M | 16.47M | 5.84M | 1.53M | 2.30M | 15.10M | 13.40M | -5.20M |
Gross Profit Ratio | 93.49% | 0.00% | 0.00% | 100.00% | 96.66% | 98.55% | 97.60% | 87.96% | 98.51% | 99.60% | 0.00% | 0.00% | 100.00% | 100.00% | 71.62% | 61.42% | 100.00% | 96.78% | 96.27% | 96.61% | 97.50% | 93.68% | 304.14% | 2,300.00% | 114.39% | 113.56% | -57.14% |
Research & Development | 36.90M | 39.14M | 25.94M | 24.11M | 36.47M | 32.87M | 64.96M | 76.63M | 86.46M | 33.62M | 62.31M | 34.90M | 27.03M | 30.18M | 51.61M | 72.02M | 61.99M | 68.77M | 101.13M | 89.53M | 58.76M | 44.67M | 26.57M | 27.70M | 29.20M | 27.30M | 0.00 |
General & Administrative | 0.00 | 0.00 | 17.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 84.83M | 56.20M | 17.63M | 19.16M | 21.18M | 31.44M | 45.31M | 53.96M | 56.24M | 42.29M | 38.24M | 38.29M | 48.04M | 57.73M | 41.61M | 35.32M | 35.30M | 61.72M | 78.52M | 55.64M | 49.80M | 35.27M | 20.42M | 9.80M | 11.60M | 10.10M | 7.60M |
Other Expenses | 8.51M | -161.00K | 4.20M | 1.32M | 0.00 | 0.00 | -5.08M | 253.00K | 2.72M | 155.00K | 30.05M | 0.00 | 0.00 | 0.00 | -7.79M | 913.00K | 792.00K | -69.96M | 2.29M | 1.34M | 6.70M | 9.39M | 10.43M | 2.20M | 1.90M | 1.60M | 1.80M |
Operating Expenses | 130.23M | 95.33M | 47.77M | 43.26M | 57.65M | 64.30M | 105.19M | 130.84M | 145.42M | 75.91M | 100.55M | 73.19M | 75.07M | 87.90M | 85.44M | 108.25M | 98.09M | 60.53M | 181.94M | 146.51M | 115.26M | 89.33M | 57.43M | 39.70M | 42.70M | 39.00M | 9.40M |
Cost & Expenses | 133.75M | 95.33M | 47.77M | 43.26M | 58.53M | 64.67M | 106.57M | 132.78M | 146.31M | 76.05M | 100.55M | 73.19M | 75.07M | 87.90M | 88.68M | 108.30M | 98.09M | 61.05M | 183.05M | 147.35M | 115.68M | 89.72M | 56.40M | 37.50M | 40.80M | 37.40M | 23.70M |
Interest Income | 1.68M | 38.00K | 204.00K | 1.17M | 1.22M | 0.00 | -2.61M | -2.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 13.14M | 2.42M | 1.03M | 1.52M | 1.73M | 2.04M | 2.83M | 2.49M | 2.68M | 1.54M | 56.00K | 1.04M | 2.33M | 4.81M | 8.56M | 14.83M | 44.58M | 17.56M | 10.99M | 9.33M | 11.24M | 5.99M | 544.29K | 0.00 | 400.00K | 0.00 | 500.00K |
Depreciation & Amortization | -56.00K | -161.00K | 204.00K | 3.29M | 593.00K | 717.00K | 831.00K | 990.00K | 1.10M | 1.57M | 2.35M | 2.41M | 1.84M | 1.77M | 5.23M | 4.69M | 6.50M | 10.28M | 11.43M | 8.44M | 14.24M | 12.24M | 10.43M | 2.20M | 1.90M | 1.60M | 1.80M |
EBITDA | -79.85M | -95.33M | -47.77M | -37.43M | -32.90M | -39.52M | -49.16M | -116.67M | -86.23M | -39.63M | -98.97M | -58.91M | -74.76M | -81.56M | -77.28M | -132.99M | -98.60M | -57.73M | -229.88M | -112.27M | -98.79M | -62.05M | -40.95M | -34.10M | -22.70M | -21.40M | -11.60M |
EBITDA Ratio | -148.02% | 0.00% | 0.00% | -1,118.83% | -102.67% | -150.79% | -84.23% | -719.40% | -149.13% | -114.29% | 0.00% | 0.00% | -24,597.49% | -111,022.50% | -1,454.18% | -93,375.59% | -105,916.25% | -464.01% | -776.77% | -453.32% | -144.55% | -995.00% | -8,156.98% | -34,100.00% | -171.97% | -181.36% | -127.47% |
Operating Income | -79.80M | -95.33M | -47.77M | -40.71M | -32.90M | -39.52M | -49.16M | -116.67M | -86.23M | -41.53M | -101.50M | -62.19M | -74.76M | -81.56M | -77.28M | -132.99M | -98.60M | -57.73M | -240.83M | -122.59M | -98.79M | -83.49M | -55.90M | -37.40M | -27.60M | -25.60M | -14.60M |
Operating Income Ratio | -147.91% | 0.00% | 0.00% | -1,217.07% | -125.14% | -157.16% | -85.64% | -723.91% | -143.54% | -119.75% | 0.00% | 0.00% | -23,434.17% | -101,948.75% | -676.02% | -104,713.39% | -123,250.00% | -358.77% | -813.77% | -494.99% | -584.68% | -1,338.76% | -11,134.98% | -37,400.00% | -209.09% | -216.95% | -160.44% |
Total Other Income/Expenses | -13.20M | -2.58M | -4.68M | 688.00K | 3.55M | -1.31M | -3.79M | -4.10M | -8.00M | -2.02M | -190.00K | -429.00K | -20.64M | -13.84M | -102.75M | -5.12M | -37.22M | -44.77M | -11.47M | -7.45M | 48.88M | 9.20M | 4.52M | 1.70M | 3.00M | 2.90M | 1.20M |
Income Before Tax | -92.99M | -97.91M | -52.45M | -40.02M | -29.35M | -40.83M | -52.95M | -120.76M | -94.23M | -43.55M | -101.69M | -62.62M | -95.40M | -95.40M | -180.03M | -138.11M | -135.82M | -102.51M | -252.30M | -130.03M | -49.90M | -74.29M | -51.38M | -35.70M | -24.60M | -22.70M | -13.40M |
Income Before Tax Ratio | -172.37% | 0.00% | 0.00% | -1,196.50% | -111.65% | -162.38% | -92.24% | -749.34% | -156.85% | -125.58% | 0.00% | 0.00% | -29,904.39% | -119,243.75% | -1,574.78% | -108,746.46% | -169,773.75% | -636.99% | -852.53% | -525.06% | -295.35% | -1,191.23% | -10,235.12% | -35,700.00% | -186.36% | -192.37% | -147.25% |
Income Tax Expense | -1.95M | 1.73M | 500.00K | 2.29M | 5.28M | 723.00K | -963.00K | -1.60M | -5.32M | -485.00K | -134.00K | 609.00K | -3.41M | 1.79M | -85.79M | -362.00K | 51.35M | 48.78M | -76.87M | 11.21M | 71.36M | 15.19M | 5.06M | 1.70M | 3.40M | 2.90M | 1.70M |
Net Income | -91.04M | -99.64M | -52.95M | -42.32M | -29.32M | -40.67M | -52.01M | -119.42M | -93.37M | -42.74M | -101.37M | -62.36M | -82.64M | -95.40M | -180.03M | -138.11M | -135.82M | -102.51M | -252.30M | -130.03M | -49.90M | -80.27M | -51.93M | -36.30M | -25.00M | -23.00M | -13.90M |
Net Income Ratio | -168.76% | 0.00% | 0.00% | -1,265.08% | -111.53% | -161.74% | -90.60% | -741.02% | -155.41% | -123.26% | 0.00% | 0.00% | -25,906.58% | -119,243.75% | -1,574.78% | -108,746.46% | -169,773.75% | -636.99% | -852.53% | -525.06% | -295.35% | -1,287.25% | -10,343.54% | -36,300.00% | -189.39% | -194.92% | -152.75% |
EPS | -0.79 | -1.11 | -0.74 | -0.73 | -0.52 | -1.12 | -1.86 | -4.26 | -6.29 | -3.74 | -17.44 | -18.18 | -36.21 | -62.44 | -1.86K | -9.15K | -14.52K | -19.06K | -56.02K | -46.71K | -17.74K | -28.49K | -24.59K | -28.03K | -19.47K | -17.95K | -12.81K |
EPS Diluted | -0.79 | -1.11 | -0.74 | -0.73 | -0.52 | -1.12 | -1.86 | -4.26 | -6.29 | -3.74 | -17.44 | -18.18 | -36.21 | -62.44 | -1.86K | -9.15K | -14.52K | -19.06K | -56.02K | -46.71K | -17.74K | -28.49K | -24.59K | -28.03K | -19.47K | -17.95K | -12.81K |
Weighted Avg Shares Out | 114.69M | 90.12M | 71.14M | 57.97M | 56.07M | 36.45M | 27.95M | 28.05M | 14.85M | 11.42M | 5.81M | 3.43M | 2.28M | 1.53M | 96.56K | 15.10K | 9.36K | 5.38K | 4.50K | 2.78K | 2.81K | 2.82K | 2.11K | 1.30K | 1.28K | 1.28K | 1.09K |
Weighted Avg Shares Out (Dil) | 114.69M | 90.12M | 71.14M | 57.97M | 56.07M | 36.45M | 27.95M | 28.05M | 14.85M | 11.42M | 5.81M | 3.43M | 2.28M | 1.53M | 96.56K | 15.10K | 9.36K | 5.38K | 4.50K | 2.78K | 2.81K | 2.82K | 2.11K | 1.30K | 1.28K | 1.28K | 1.09K |
CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Wednesday, June 16
CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q1 2021 Results - Earnings Call Transcript
CTI BioPharma Reports First Quarter 2021 Financial Results
CTI BioPharma Shares Shoot Higher as FDA Accepts Pacritinib Review Application In Bone Marrow Cancer
CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis
7 Reddit Penny Stocks Promising to Cure Cancer
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CTI BioPharma to Report First Quarter 2021 Financial Results on June 1, 2021
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7 Penny Stocks That May Not Be Penny Stocks For Long
Source: https://incomestatements.info
Category: Stock Reports